Search

Displaying results 3451 - 3460 of 10000 in total
  1. Drug

    Sovateltide

    go.drugbank.com/drugs/DB06138
    Investigational

    It is being developed as an adjunct to chemotherapy. … SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor.

  2. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. … This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.

  3. Drug

    Rose bengal I-131

    go.drugbank.com/drugs/DB09388
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    related and memory related tasks (Kitagawa, et al. … In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention

    Synonyms: DMXB-A
  5. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid [L1496]. … In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with bronchitis showed improvement [A7889].

  6. Drug

    Ambrosia artemisiifolia pollen

    go.drugbank.com/drugs/DB10385
    Approved

    Ambrosia artemisiifolia pollen is mainly used in allergenic testing.

    Products: Center-AL - Ambrosia Artemisiifolia Pollen, LAIS Ambrosia 1000 UA Sublingualtabletten
  7. Drug

    Rapacuronium

    go.drugbank.com/drugs/DB04834
    ApprovedWithdrawn

    Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

  8. Target

    Cyclin-dependent kinase 7

    go.drugbank.com/bio_entities/BE0001913
    TargetHumans

    Catalytic subunit of the CDK-activating kinase (CAK) complex, a master regulator of CDK activity by catalyzing the activating threonine phosphorylation of CDKs (PubMed:41100585). … Initiates transcription by RNA polymerase II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting dissociation from

    Synonyms: TFIIH basal transcription factor complex kinase subunit
  9. Drug

    Aldesleukin

    go.drugbank.com/drugs/DB00041
    ApprovedInvestigational

    Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. … This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon

    Synonyms: 125-L-Serine-2-133-interleukin 2, 125-L-serine-2-133-interleukin 2 (human reduced)
  10. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    isomer as [DB00470], or in a 1:1 formulation with CBD from purified plant extract as [DB14011]. … In Canada, Sativex® has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded